>>> bb/110769@110727
In order No. 183n there is no indication of INN "atropine". Thus, this drug is not accounting. However, Schedule II of this order includes the atropine isomer, the "L-stereoisomer of atropine." In this regard, some experts believe that atropine itself is subject to quantitative accounting.
To clarify this situation in June, the Association “Pharmacy Guild” appealed to the Ministry of Health for comment. The Ministry in a letter dated June 23, 2021 No. 25-4/1216 replied that since Order No. 183n mentions the atropine isomer, the substance itself is subject to subject-quantitative accounting.
Now, in a new information letter dated July 15, 2021 No. 25-4/1399, the Ministry of Health informs that it withdraws the previous letter and gives new clarifications on atropine.
The letter says that atropine drugs have a psychoactive effect on the human body only in case of overdose. However, when used in therapeutic doses, psychoactive effects are not noted. Cases of the formation of mental or physical dependence with the medical use of these drugs have not been registered. Thus, the Department of Drug Supply and Regulation of the Circulation of Medical Devices of the Ministry of Health considers it inappropriate to include atropine drugs in the list of drugs subject to subject-quantitative accounting.